ClinicalTrials.gg
CompletedNCT03000075Updated May 21, 2019Results posted

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

A Phase 2 interventional study of risankizumab and placebo for risankizumab in Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-05-21.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing risankizumab in Psoriasis — 1 open to participants now, 2 under way, 1 of them phase 3. risankizumab · Psoriasis.

Enrollment
13th of 30
182 · median 162
Started
2016
with 5 others
Phase 2
4 of 30
none open now
Registered
9th of 30
by date
Lead sponsor
24 of 30
AbbVie

Among the 30 studies testing risankizumab in Psoriasis, this one is the 13th largest by enrollment, is one of 6 that started in 2016, is one of 4 in phase 2, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 30 studies testing risankizumab in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About risankizumab

risankizumab: first FDA approval 2019 (SKYRIZI), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing risankizumab in Psoriasis, or all of them as a file.
02

Study summary

This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).

Read the detailed description

Participants were randomized to receive either placebo, risankizumab 75 mg, or risankizumab 150 mg in Part A. All participants received 2 injections to maintain the blind: the placebo arm received 2 injections of placebo, the risankizumab 75 mg arm received one injection of risankizumab 75 mg and one injection of placebo, and the risankizumab 150 mg arm received 2 injections of risankizumab 75 mg. Participants who received placebo in Part A switched to risankizumab in Part B; participants who received risankizumab (75 mg or 150 mg) in Part A continued to receive the same treatment (risankizumab 75 mg or 150 mg) in Part B.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • BI 655066
  • ABBV-066
  • risankizumab
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the patient.
  • Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation):

    1. Have an involved body surface area (BSA) ≥10% and
    2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and
    3. Have a Static Physician Global Assessment (sPGA) score of ≥3.

Exclusion criteria

Exclusion Criteria:

  • Patients with

    1. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)
    2. current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
    3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigator's judgment
  • Previous exposure to BI 655066
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
182 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Part A)

    Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).

    Drug: placebo for risankizumab

  • Experimental
    Risankizumab 75 mg (Part A)

    Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).

    Drug: risankizumab · Drug: placebo for risankizumab

  • Experimental
    Risankizumab 150 mg (Part A)

    Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).

    Drug: risankizumab

Interventions

  • Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

    Also known as: ABBV-066, BI 655066

  • Drugplacebo for risankizumab

    Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving PASI90 at Week 52 (Part B)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 52

  2. Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

  3. Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B)

    The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 52

  4. Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

  5. Percentage of Participants Achieving PASI75 at Week 52 (Part B)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 52

  6. Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

  7. Percentage of Participants Achieving PASI100 at Week 52 (Part B)

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 52

  8. Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A)

    Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

  9. Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B)

    Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 52

07

Results

Posted Feb 6, 2019

Participant flow

Part A
Participant flow — Part A
MilestonePlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Placebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Started5858550000
Completed5458550000
Not completed4000000
Withdrew: Adverse event4000000
Part B
Participant flow — Part B
MilestonePlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Placebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Started00027275855
Completed00027265654
Not completed0000121
Withdrew: Not dosed due to ae0000021
Withdrew: Adverse event0000100

Outcome measures

PrimaryPercentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)
percentage of participantsPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)1.775.974.5
Statistical analysis
  • Placebo (Part A) vs Risankizumab 75 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 73.6 · 95% CI 62.2 to 85.095% confidence interval (CI) for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
  • Placebo (Part A) vs Risankizumab 150 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 72.4 · 95% CI 60.6 to 84.195% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
SecondaryPercentage of Participants Achieving PASI90 at Week 52 (Part B)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI90 at Week 52 (Part B)
percentage of participantsPlacebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Percentage of Participants Achieving PASI90 at Week 52 (Part B)81.585.286.292.7
SecondaryPercentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)
percentage of participantsPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)10.386.292.7
Statistical analysis
  • Placebo (Part A) vs Risankizumab 75 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 75.0 · 95% CI 63.8 to 86.295% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
  • Placebo (Part A) vs Risankizumab 150 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 82.4 · 95% CI 72.2 to 92.695% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
SecondaryPercentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B)

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \>0, \<1.5; Mild (2) = mean ≥1.5, \<2.5; Moderate (3) = mean ≥2.5, \<3.5; and Severe (4) = mean ≥3.5. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B)
percentage of participantsPlacebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B)96.388.984.594.5
SecondaryPercentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A)
percentage of participantsPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)
Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A)8.689.794.5
Statistical analysis
  • Placebo (Part A) vs Risankizumab 75 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 80.3 · 95% CI 70.1 to 90.495% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
  • Placebo (Part A) vs Risankizumab 150 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 86.0 · 95% CI 76.8 to 95.195% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
SecondaryPercentage of Participants Achieving PASI75 at Week 52 (Part B)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI75 at Week 52 (Part B)
percentage of participantsPlacebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Percentage of Participants Achieving PASI75 at Week 52 (Part B)10088.994.896.4
SecondaryPercentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A)
percentage of participantsPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)
Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A)022.432.7
Statistical analysis
  • Placebo (Part A) vs Risankizumab 75 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 22.6 · 95% CI 11.8 to 33.495% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
  • Placebo (Part A) vs Risankizumab 150 mg (Part A) · Cochran-Mantel-Haenszel · p = < 0.001 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 32.5 · 95% CI 20.0 to 45.095% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
SecondaryPercentage of Participants Achieving PASI100 at Week 52 (Part B)

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI100 at Week 52 (Part B)
percentage of participantsPlacebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Percentage of Participants Achieving PASI100 at Week 52 (Part B)40.744.443.141.8
SecondaryPercentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A)

Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A)
percentage of participantsPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A)040.033.3
Statistical analysis
  • Placebo (Part A) vs Risankizumab 75 mg (Part A) · Cochran-Mantel-Haenszel · p = 0.131 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 39.2 · 95% CI -11.6 to 90.195% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
  • Placebo (Part A) vs Risankizumab 150 mg (Part A) · Cochran-Mantel-Haenszel · p = 0.269 (P-value was calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.) · Adjusted percentage difference: 31.3 · 95% CI -24.2 to 86.795% CI for adjusted difference of 2 treatment groups, calculated from the Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count, 0.1 was added to each cell.
SecondaryPercentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B)

Response defined by ACR20 criteria (improvement from baseline): ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient assessment of pain; Patient global assessment of disease activity; Investigator's global assessment of disease activity; Health Assessment Questionnaire Disability Index (HAQ-DI); and Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B)
percentage of participantsPlacebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab150 mg /Risankizumab 150 mg (Part B)
Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B)10010060.00

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 16 weeks after the last dose of study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Part A)0/58 (0%)1/58 (1.7%)22/58 (37.9%)
Risankizumab 75 mg (Part A)0/58 (0%)2/58 (3.4%)14/58 (24.1%)
Risankizumab 150 mg (Part A)0/55 (0%)2/55 (3.6%)14/55 (25.5%)
Placebo/Risankizumab 75 mg (Part B)0/27 (0%)2/27 (7.4%)10/27 (37%)
Placebo/Risankizumab 150 mg (Part B)0/27 (0%)0/27 (0%)19/27 (70.4%)
Risankizumab 75 mg/Risankizumab 75 mg (Part B)0/56 (0%)1/56 (1.8%)23/56 (41.1%)
Risankizumab 150 mg/Risankizumab 150 mg (Part B)0/54 (0%)1/54 (1.9%)19/54 (35.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Placebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab 150 mg/Risankizumab 150 mg (Part B)
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/580/580/551/270/270/560/54
Loss of consciousnessNervous system disorders0/580/580/551/270/270/560/54
Rectal polypGastrointestinal disorders0/580/580/550/270/270/561/54
Acute myocardial infarctionCardiac disorders0/580/581/550/270/270/560/54
Erythrodermic psoriasisSkin and subcutaneous tissue disorders0/580/581/550/270/270/560/54
Dermal cystSkin and subcutaneous tissue disorders0/580/580/550/270/271/560/54
Pneumonia bacterialInfections and infestations1/580/580/550/270/270/560/54
PsoriasisSkin and subcutaneous tissue disorders0/581/580/550/270/270/560/54
HypotensionVascular disorders0/581/580/550/270/270/560/54
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Placebo/Risankizumab 75 mg (Part B)Placebo/Risankizumab 150 mg (Part B)Risankizumab 75 mg/Risankizumab 75 mg (Part B)Risankizumab 150 mg/Risankizumab 150 mg (Part B)
NasopharyngitisInfections and infestations8/583/5810/558/278/2712/5611/54
PsoriasisSkin and subcutaneous tissue disorders9/582/580/550/271/270/560/54
ArthralgiaMusculoskeletal and connective tissue disorders1/580/582/553/273/270/560/54
Dental cariesGastrointestinal disorders1/580/580/550/271/271/564/54
VomitingGastrointestinal disorders1/580/580/550/272/270/561/54
Oral herpesInfections and infestations0/580/580/550/272/270/560/54
Back painMusculoskeletal and connective tissue disorders1/582/581/552/271/272/561/54
AsthmaRespiratory, thoracic and mediastinal disorders0/580/580/552/270/270/561/54
AsteatosisSkin and subcutaneous tissue disorders0/580/580/552/270/270/560/54
Tinea pedisInfections and infestations2/581/580/550/271/270/563/54

Baseline characteristics

Intent-to-treat (ITT) population: all participants who were randomized.

Age, Continuous
Age, Continuous(years)Placebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Total
Mean50.9 ± 11.2451.5 ± 12.3353.3 ± 11.9451.9 ± 11.82
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Total
Female1310528
Male454850143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Total
Hispanic or Latino0000
Not Hispanic or Latino585855171
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Part A)Risankizumab 75 mg (Part A)Risankizumab 150 mg (Part A)Total
American Indian or Alaska Native0000
Asian585855171
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clin Pharmacokinet. 2020 May;59(5):575-589. doi: 10.1007/s40262-019-00829-2. PubMed 31667790 ↗
  • Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, Kitamura S, Valdes J, Igarashi A. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. J Dermatol. 2019 Aug;46(8):686-694. doi: 10.1111/1346-8138.14941. Epub 2019 Jun 25. PubMed 31237727 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Sep 2017, 9 months.

Results were first posted in Feb 2019, 1 year 4 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Dec 21, 2016
StartActual
Dec 2, 2016
Primary completionActual
Sep 21, 2017
CompletionActual
Jun 20, 2018
Results first posted
Feb 6, 2019
Last update
May 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03000075
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Dec 2, 2016
Primary completion
Sep 21, 2017
Completion
Jun 20, 2018
Results posted
Feb 6, 2019
Last update
May 21, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion